Eli Lilly and Company $LLY Stock Sold by Artemis Investment Management LLP

Artemis Investment Management LLP decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 20.5% during the third quarter, according to its most recent filing with the SEC. The firm owned 76,310 shares of the company’s stock after selling 19,638 shares during the period. Artemis Investment Management LLP’s holdings in Eli Lilly and Company were worth $88,297,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the business. Osbon Capital Management LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $25,000. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth approximately $30,000. Maseco LLP lifted its stake in shares of Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after buying an additional 28 shares in the last quarter. Aventus Investment Advisors Inc. boosted its holdings in shares of Eli Lilly and Company by 270.0% during the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after purchasing an additional 27 shares during the last quarter. Finally, Marshall & Sterling Wealth Advisors Inc. raised its holdings in shares of Eli Lilly and Company by 60.0% during the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after acquiring an additional 15 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analyst raises price target: Cantor Fitzgerald lifted its LLY price target to $1,440 from $1,410 and maintained an “overweight” rating, signaling confidence in Lilly’s long-term earnings outlook. Benzinga coverage
• Positive Sentiment: Technical momentum improves: LLY recently moved above its 50-day moving average, a technical signal that may attract short-term buyers and suggests improving near-term momentum. Eli Lilly overtakes 50-day moving average
• Positive Sentiment: Pipeline supports the long-term case: Investors continue to highlight strong GLP-1 demand, oncology growth and next-generation obesity candidate retatrutide. Retatrutide’s potential efficacy and a possible FDA filing in 2027 could provide another major growth catalyst. Three bargains outside AI
• Neutral Sentiment: Oncology remains a developing growth driver: Jaypirca, Inluriyo and Retevmo could help offset slower Verzenio sales and declines from mature products, although the financial impact will depend on commercial execution and upcoming results. Eli Lilly oncology portfolio ahead of earnings
• Negative Sentiment: Valuation and competition remain overhangs: Analysts note that LLY trades at a demanding multiple, while increasing competition in the GLP-1 market and potential pricing pressure could limit the pace of future earnings growth. New WHO childhood-obesity guidance may also create uncertainty around the market’s long-term expansion. Is the LLY dip a buying opportunity?

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an “overweight” rating in a report on Monday, September 28th. TD Cowen reaffirmed a “buy” rating and set a $1,250.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. UBS Group set a $1,376.00 price target on shares of Eli Lilly and Company in a research note on Friday, August 7th. Cantor Fitzgerald raised their price target on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Truist Financial upped their price objective on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $1,313.43.

Eli Lilly and Company Trading Down 3.3%

Shares of NYSE:LLY traded down $39.79 during trading on Thursday, hitting $1,148.93. 1,507,727 shares of the company’s stock were exchanged, compared to its average volume of 2,966,079. The firm has a 50-day moving average price of $1,173.51 and a two-hundred day moving average price of $1,094.59. The firm has a market cap of $1.08 trillion, a P/E ratio of 38.63, a PEG ratio of 1.42 and a beta of 0.46. Eli Lilly and Company has a 1-year low of $783.85 and a 1-year high of $1,292.65. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the firm earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts predict that Eli Lilly and Company will post 36.66 earnings per share for the current year.

Insider Activity at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.